Xenon Pharmaceuticals Inc.
XENE
$58.81
-$0.74-1.24%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 32.33% | 44.62% | 47.46% | 35.25% | 50.87% |
| Gross Profit | -32.33% | -64.82% | -47.46% | -35.25% | -50.87% |
| SG&A Expenses | 24.36% | 25.12% | 22.57% | 15.42% | -0.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.70% | 39.99% | 41.68% | 30.76% | 36.36% |
| Operating Income | -30.70% | -54.43% | -41.68% | -30.76% | -36.36% |
| Income Before Tax | -30.46% | -62.29% | -50.61% | -42.96% | -46.48% |
| Income Tax Expenses | 6.55% | -702.11% | 113.98% | 311.56% | -87.99% |
| Earnings from Continuing Operations | -30.73% | -57.27% | -60.25% | -44.76% | -46.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.73% | -57.27% | -60.25% | -44.76% | -46.24% |
| EBIT | -30.70% | -54.43% | -41.68% | -30.76% | -36.36% |
| EBITDA | -30.98% | -55.03% | -42.11% | -31.07% | -36.71% |
| EPS Basic | -3.62% | -41.69% | -56.77% | -42.34% | -43.86% |
| Normalized Basic EPS | -3.40% | -46.19% | -47.35% | -40.56% | -44.09% |
| EPS Diluted | -3.62% | -41.69% | -56.77% | -42.34% | -43.86% |
| Normalized Diluted EPS | -3.40% | -46.19% | -47.35% | -40.56% | -44.09% |
| Average Basic Shares Outstanding | 26.16% | 11.00% | 2.22% | 1.70% | 1.65% |
| Average Diluted Shares Outstanding | 26.16% | 11.00% | 2.22% | 1.70% | 1.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |